Amyotrophic Lateral Sclerosis {#S1}
=============================

The diagnosis of amyotrophic lateral sclerosis (ALS) can only be fully confirmed by the post mortem detection of ALS-associated protein inclusions such as TDP-43 and SOD1 ([@B173]). Coupled with the spectrum of symptoms seen in the clinical presentation of ALS, the diagnosis of ALS relies on presentation to a neurologist and the elimination of other neurological and/or muscular diseases such as Kennedy's disease or myasthenia gravis, based on the El Escorial criteria that requires the assessment of disease progression ([@B17]; [@B100]; [@B8]; [@B71]). This results in the average time from onset of symptoms after diagnosis of ALS being 10 months, in a disease with survival of 24--48 months ([@B24]; [@B71]).

Defined as characteristic that is objectively measured and evaluated as an indicator of normal biological process, pathogenic process, or a pharmacogenomic process to therapeutic intervention, biomarkers include genomics, proteomics, metabolomics, neurophysiology, and neuroimaging ([@B51]; [@B174]). The lack of a reliable biomarker for ALS hampers a rapid, definitive diagnosis of disease, determination of ALS subtypes, monitoring of disease progression in patients, and limits the ability of clinicians and scientists to achieve an unbiased assessment of the efficiency of new treatments ([@B175]; [@B51]). For patients and their families, a sensitive and specific biomarkers could allow detection of ALS at early stages, and allow the prognosis of the clinical subtype of ALS to predict disease aggressivity and subtype ([@B51]; [@B8]). This research gap in biomarker discovery and development for ALS comes not only as an impediment for patients and their families, but also at a cost to the pharmaceutical industries, through the monitoring of drug effects and disease progression in clinical trials. In particular, the repeated failure of drugs demonstrating clinical efficacy, and the inability to detect improvements, or non-improvements rapidly ([@B5]; [@B51]; [@B143]).

The Kynurenine Pathway {#S2}
======================

One of the hallmarks of ALS is the presence of neuroinflammation and the kynurenine pathway (KP) is known to be strongly induced by inflammatory cytokines such as IFN-γ ([@B115]; [@B121]; [@B23]; [@B136]). The KP is the major route of tryptophan (TRP) catabolism, and feeds into the serotonin pathway, immune related tetrahydrobiopterin (BH4) pathway, glycolysis, and *de novo* nicotinamide adenine dinucleotide (NAD+) pathway ([Figure 1](#F1){ref-type="fig"}) ([@B165]; [@B56]; [@B133]; [@B155]); linking it to fatigue, depression, inflammation, and decrease in energy metabolism ([@B153]; [@B56]; [@B133]).

![The Kynurenine Pathway and its downstream pathways of Serotonin/Melatonin, BH4, Glycolysis, and NAD+. Tryptophan is converted into serotonin and melatonin, that regulate mood and sleep. The tetrahydrobiopterin (BH4) pathway interacts with the KP in three ways, (1) the sharing of the enzyme TPH that degrades tryptophan, (2) the inhibition of a key BH4 pathway enzyme, sepiapterin reductase, (3) both BH4 and KP are induced by inflammatory cytokines. Tryptophan also feeds into the glycolysis cycle via ACMS, affecting ATP production. Finally, the KP is the *de novo* synthesis pathway of NAD+ which is associated with cellular energy, repair and fatigue. The key KPMs are bolded, neurotoxic metabolites represented in red, neuroprotective metabolites in green, and dual functioning in blue.](fnins-13-01013-g001){#F1}

The essential amino acid tryptophan originates from the diet, if which up to 85% is bound to albumin in blood circulation, and 99% metabolized in the liver ([@B148]; [@B184]; [@B9]). Activation of the KP is achieved by the triggering of the first enzyme of the pathway, indoleamine 2,3 dioxygenase (IDO1) ([@B63]; [@B9]). This results in the production of several neuroactive metabolites such as the excitotoxins quinolinic acid (QUIN), and 3-hydroxykynurenine (3HK) by activated monocytic cells ([@B65]); and the neuroprotective kynurenic acid (KA) and picolinic acid (PIC) by astrocytes and neurons, respectively ([@B77]; [@B14]; [@B67], [@B66]; [@B9]). The KP is active in most cell types, particularly in the liver ([@B171]; [@B76]), and is highly activated in monocytic cells during inflammation ([@B87]). Only a limited number of KP can cross the blood brain barrier (BBB). TRP, Kynurenine (KYN), 3HK, anthranilic acid (AA) are actively transported by the large neutral amino acid carrier system; and others via passive diffusion ([@B47]; [@B151]). This indicates that peripheral activation of the KP by inflammation can be translocated to the central nervous system (CNS), altering immune regulation and increasing neurotoxicity ([@B132]). In the CNS, most cells contain the complete set of KP enzymes, and are capable of degrading TRP ([@B63]; [@B101]). However, neurons, astrocytes and oligodendrocytes are incapable of synthesizing QUIN, only activated microglia and infiltrating macrophages produce QUIN ([@B68]; [@B107]).

The concept of using kynurenine pathway metabolites (KPMs) as markers for diseases dates back to the 1950s ([@B123]; [@B172]), where excretion of KPMs were observed in the urine of patients diagnosed with cancer, rheumatoid arthritis, cardiovascular events and fevers ([@B123]; [@B170]; [@B172]; [@B117]; [@B116]; [@B114]). More recently, the KP is investigated mostly in other liquid biopsies such as serum and plasma ([@B105]). The levels of the KPMs has been shown to be well correlated between the cerebrospinal fluid (CSF) and blood ([@B32]; [@B23]; [@B125]; [@B83]), however, they are not always identical; and only few studies ([@B32]; [@B180]; [@B23]; [@B189]; [@B73]; [@B106]; [@B83]) correlate the KP levels in different biofluids from the same patients at the same time. KPMs have been historically measured using thin layer chromatography, and detected under UV light, or via radioactive metabolites ([@B123], [@B124]; [@B117]; [@B116]; [@B160]). Today, KPMs are more often measured using more sensitive methods and equipment such as high performance liquid chromatography (HPLC), Gas chromatography mass spectrometry (GCMS), and liquid chromatography tandem mass spectrometry (LC-MS/MS) ([@B78]; [@B15]; [@B162]; [@B37]; [@B138]; [@B120]). The most commonly measured KPMs are TRP, KYN, and KYNA, and are often presented as ratios. As they are small molecules, the KPMs such as KYN, KYNA, Xanthurenic acid (XA) and AA have been shown to be stable. With the exception of 3-hydroxy anthranilic acid (3HAA), which is known to be particularly unstable over time and sensitive to light ([@B33]; [@B119]).

*Ex vivo*, the KPMs have been measured using immunohistochemistry (IHC) in tissue sections ([@B61]; [@B164]; [@B108]). More recently, techniques such as tissue-based Matrix-assisted laser desorption/ionization (MALDI) Mass spectrometry Imaging (MSI) and tissue microarray has been used to not only detect, but localize the presence of TRP and KYN in tumors *ex vivo* ([@B147]; [@B6]). This specific localization will allow for focal observation of KPMs changes within tissue, and targeted applications of monitoring and altering of the KP if this can be translated *in vivo*.

Using the levels of KPMs, the activity of their associated enzymes can be derived as a proxy of the concentrations of direct derivatives of the metabolites as a ratio ([@B34]; [@B157]; [@B108]) -- most commonly measuring IDO1 via the Kynurenine: Tryptophan ratio (K/T ratio; KTR); or via direct enzymatic assays ([@B157]). Although few studies have looked at the direct correlation between metabolite ratio and enzymatic concentrations ([@B10]).

*In vitro*, neurotoxic KPMs such as QUIN and 3HK, have been shown to induce neurodegeneration and neuronal cell death through excitotoxicity, *N*-methyl-[D]{.smallcaps}-aspartate (NMDA) receptor antagonism, increased glutamate release, and the production of reactive oxygen species ([@B93]; [@B95]; [@B92]; [@B126]; [@B161]; [@B58]; [@B103]; [@B60]; [@B89]; [@B144]). The neurotoxic mechanisms of QUIN is well established, and overlaps with mechanisms of neurodegeneration in ALS such as excitotoxicity, hyperphosphorylation, and protein dysfunction ([@B145]; [@B59]; [@B101]). Some of the KPMs such as KYNA, PIC, and 3HAA have neuroprotective and immunomodulatory properties ([@B44]; [@B13]; [@B57]; [@B97]; [@B110]). Other KPMs such as 3HAA, have both neurotoxic and neuroprotective functions depending on their relative concentrations ([@B28]; [@B140]). The KPMs can influence each other levels ([@B141]; [@B85]), and the balance of KPMs is crucial for managing the equilibrium between neurotoxicity and neuroprotection. The dysregulation of KPMs, especially excessive QUIN production, has been correlated with variations of other neuroinflammatory markers ([@B75]; [@B64]; [@B88]), making the modulation of KPMs a plausible target for the regulation of the immune response within the CNS ([@B166]; [@B16]; [@B84]).

Using these modern techniques, the KP has been investigated as a marker for progression, severity, and prognostic for diseases such as systemic lupus erythematosus ([@B142]; [@B7]), cancers ([@B86]; [@B189]; [@B181]; [@B80]; [@B109]; [@B91]), cardiovascular disease ([@B169]; [@B189]), lung cancer and chronic obstructive pulmonary disease ([@B26]; [@B188]), chronic kidney disease and diabetes ([@B79]; [@B187]), acquired immunodeficiency syndrome (AIDS) and HIV-dementia ([@B46]; [@B74]; [@B154]; [@B62]; [@B41]; [@B102]; [@B177]), pancreatic cysts ([@B137]), acute myeloid leukemia and lymphomas ([@B54]; [@B43]), vitamin levels ([@B119]), tuberculosis ([@B178]; [@B42]), malaria ([@B118]), irritable bowel syndrome (IBS) ([@B27]; [@B70]), rheumatoid arthritis ([@B163]; [@B158]), growth deficits ([@B96]), obesity ([@B113]), and preeclampsia ([@B128]). In the nervous system, the KP has been shown to associate with pathologies such as stroke ([@B34]), schizophrenia ([@B122]; [@B90]; [@B134]), Parkinson's ([@B129]; [@B180]; [@B105]; [@B73]), neuropsychiatric disorders such as depression and stress ([@B111]; [@B50]; [@B130]; [@B164]; [@B94]; [@B40]; [@B30]; [@B98]; [@B80]; [@B99]), suicide ([@B40]; [@B11]; [@B18]), multiple sclerosis ([@B149]; [@B106]), Alzheimer's disease ([@B61]; [@B72]), Huntington's disease ([@B159]; [@B12]; [@B167]; [@B20]), brain tumors ([@B2], [@B3]), Autism Spectrum Disorders, and Attention Deficit Hyperactivity Disorder (ADHD) ([@B1]; [@B19]). More recently, studies have demonstrated that the KPMs could be used for the prognosis of MS, and also to differentiate between disease subtypes ([@B4]; [@B106]).

Amyotrophic Lateral Sclerosis and Kynurenine-Associated Pathways {#S3}
================================================================

The levels of KPMs are known to be dysregulated in the serum, CSF, and tissue of ALS patients ([@B81]; [@B23]) ([Table 1](#T1){ref-type="table"}). The first study by [@B81] investigated the presence of KYNA in ALS patients and matching healthy controls. Broadly, the results did not show any significant differences in the levels of KYNA between patients and controls in either serum or CSF. However, CSF KYNA was higher in (1) patients with severe clinical status; and (2) in patients with bulbar onset, compared to patients with limb onset. The authors concluded that this increase likely associated with the neuroprotective role of KYNA. The authors also showed that the concentrations of KYNA in CSF and in serum were not correlated, indicating that KYNA in the CNS is mostly produced in the brain by astrocytes ([@B67]), and this confirms that KYNA is able to cross the BBB and may be imported from the PNS. This is supported by the presence of astrogliosis as part of the neuroinflammatory features found in ALS brain. In 2010, our team reported increased levels of TRP, KYN, and QUIN in both CSF and serum. This study did not investigate KYNA or astrogliosis as Ilzecka et al. did, however, does confirm the neuroinflammatory status in ALS patients, with presence of activated microglia and activation of the KP in the motor cortex.

###### 

Summary of Kynurenine Pathway metabolite levels in controls and ALS patients collated from Ilzecka and Chen.

  **References**   **KPM**                    **Population**                     **Serum**        **CSF**         **Trend observed**   
  ---------------- -------------------------- ---------------------------------- ---------------- --------------- -------------------- -----------------------------
  Ilzecka          Kyna pmol/ml               Control (*n* = 14)                 59.6 ± 20.5      2.41 ± 1.7                           
                                              ALS (*n* = 16)                     57.8 ± 35.0      1.59 ± 0.9      Mild \> Severe       Control \< Bulbar
                                              Bulbar (*n* = 6)                   59.5 ± 39.3      3.61 ± 2.0      Control \> Severe    Bulbar \> Limb
                                              Limb (*n* = 10)                    59.6 ± 31.2      1.70 ± 1.0      clinical status      Control \< Severe
                                              Mild clinical status (*n* = 6)     81.6 ± 41.2      1.75 ± 09                            clinical status
                                              Severe clinical status (*n* = 8)   39.9 ± 14.7      3.26 ± 2.1                           
  Chen             TRP (μM)                   Control (*n* = 17)                 75.0 ± 10.5      2.58 ± 0.16     Control \< ALS^∗∗^   Control \< ALS^∗∗^
                                              ALS(140)                           143.3 + 5.6      5.0 ± 0.2                            
                                              sALS (*n* = 133)                   133.3 ± 6.0      4.67 ± 0.19                          
                                              fALS (*n* = 7)                     166.4 ± 20.7     5.20 ± 0.87                          
                                              Bulbar (*n* = 31)                  128.2 ± 10.6     4.58 ± 0.33                          
                                              Limb (*n* = 109)                   137.3 ± 6.9      4.73 ± 0.22                          
                   KYN (μM)                   Control (*n* = 17)                 2.52 ± 0.19      0.027 ± 0.00    Control \< ALS^∗∗^   Control \< ALS^∗∗^
                                              ALS(140)                           4.0 + 0.2        0.23 + 0.02                          
                                              sALS (*n* = 133)                   4.05 ± 0.21      0.22 ± 0.01                          
                                              fALS (*n* = 7)                     3.24 ± 0.36      0.26 ± 0.05                          
                                              Bulbar (*n* = 31)                  3.99 ± 0.29      0.22 ± 0.02                          
                                              Limb (*n* = 109)                   4.00 ± 0.24      0.21 ± 0.03                          
                   PIC (μM)                   Control (*n* = 35)                 2.4 ± 0.4        0.51 ± 0.11     Control \> ALS^∗^    Control \> ALS (*p* = 0.09)
                                              ALS(140)                           1.4 + 0.1        0.36 + 0.03                          
                                              sALS (*n* = 133)                   1.46 ± 0.13      0.35 ± 0.07                          
                                              fALS (*n* = 7)                     1.80 ± 0.51      0.60 ± 0.21                          
                                              Bulbar (*n* = 31)                  1.45 ± 0.16      0.30 ± 0.06                          
                                              Limb (*n* = 109)                   1.49 ± 0.10      0.35 ± 0.07                          
                   QUIN (μM)                  Control (*n* = 35)                 0.30 ± 0.03      0.038 ± 0.004   Control \< ALS^∗^    Control \< ALS^∗^
                                              ALS(140)                           0.37 + 0.02      0.053 + 0.005                        
                                              sALS (*n* = 133)                   0.38 ± 0.02      0.05 ± 0.01                          
                                              fALS (*n* = 7)                     0.36 ± 0.04      0.04 ± 0.01                          
                                              Bulbar (*n* = 31)                  0.43 ± 0.04      0.04 ± 0.01                          
                                              Limb (*n* = 109)                   0.36 ± 0.02      0.05 ± 0.01                          
                   IDO Activity (K/T ratio)   Control (*n* = 17)                 0.039 ± 0.004    0.011 ± 0.001                        Control \< ALS
                                              ALS (*n* = 40)                     0.037 ± 0.0025   0.044 + 0.002                        
                                              sALS (*n* = 133)                   0.04 ± 0.00      0.04 ± 0.00                          
                                              fALS (*n* = 7)                     0.02 ± 0.00      0.04 ± 0.01                          
                                              Bulbar (*n* = 31)                  0.04 ± 0.00      0.04 ± 0.00                          
                                              Limb (*n* = 109)                   0.04 ± 0.00      0.04 ± 0.00                          

Mild clinical status defined as mild to moderate according to Munsat, Severe clinical status defined as severe to terminal according to Munsat. KMP, KP metabolites; Kyna, kynurenic acid; TRP, tryptophan; KYN, kynurenine; PIC, picolinic acid; QUIN, quinolinic acid; IDO, indoleamine dioxygenase; K/T ratio, kynurenine/tryptophan ratio; sALS, sporadic ALS; fALS, familial ALS.
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Other studies have indirectly reported associations between ALS and the KPMs. [@B85] showed that injections of the excitotoxin QUIN and 3HAA, directly into the rat brain, triggers a decrease in choline acetyltransferase (ChAT) activity, and that KYNA, PIC, quinaldic acid (QUINA), and AA co-injections could antagonize the QUIN-induced neurotoxicity. In addition, QUIN injections were associated with neuronal loss, but also glial proliferation, highlighting the important roles played by KPMs in neuroinflammation and glial activation in ALS.

Aside from the KP, tryptophan is also metabolized by pinealocytes into serotonin (5-HT), and then melatonin, a serotonin downstream metabolite. Pinealocytes are external to the BBB, and thus directly affected by the KP in the periphery, but not directly by the KP in the CNS ([@B151]). Within the brain, serotonin is modulated by tryptophan levels. A decrease in serotonin levels has been linked to depression through tryptophan depletion ([@B131]; [@B151]; [@B112]), and with the decrease of melatonin, and sleep disturbances, which are both symptoms in ALS patients ([@B153]). Furthermore, motoneurons affected in ALS are heavily innervated by serotoninergic neurons; whereas those resistant to ALS-associated degeneration are less innervated by serotonin neurons, possibly linking serotonin with induction of neuronal excitability and neurodegeneration. The roles of serotonin in ALS has been reviewed ([@B153]). Melatonin has been shown to confer neuroprotection in ALS patients and Cu/Zn superoxide dismutase (SOD1) mice models, likely by decreasing systemic oxidative stress, caspase activation, and by increasing ATP availability to increase cell repair mechanisms to limit neuronal death ([@B179]; [@B186]).

The metabolic pathway of tryptophan degradation also feeds into the cell's energy metabolism through the production of NAD+ and glycolysis. Its dysregulation increases the risk for the development of neurodegenerative diseases as many repair and neuroprotective systems perform at a suboptimal level. NAD+ depletion can lead to fatigue ([@B146]; [@B21]; [@B155]). Altered energy metabolism has also been investigated in ALS ([@B39]; [@B127]), and has been shown to be altered by QUIN via the respiratory chain and Krebs cycle ([@B150]; [@B29]). The NAD+ pathway represents an important therapeutic avenue, and is being targeted using precursors such as nicotinamide phosphoribosyl transferase, or nicotinamide ribosyl directed at ageing, neurodegeneration, and in particular, axonal degeneration ([@B156]; [@B82]; [@B176]; [@B139]).

A pathway that has been understudied in ALS is the tetrahydrobiopterin (BH4) pathway ([Figure 1](#F1){ref-type="fig"}). Interconnected to the KP via the modulatory effect of XA, and as a co-substrate for tryptophan hydroxylase ([@B185]; [@B31]), studies on BH4 have largely focused on inflammation, pain and neuroprotection ([@B135]; [@B52]; [@B31]). BH4 is strongly associated with neuroinflammation, and is also an essential co-factor in nitric oxide synthases in oxidative stress ([@B152]; [@B69]; [@B31]) - both pathological features present in ALS. Several reports have associated BH4 with neurodegeneration, such as the differential methylation of BH4 in monozygotic twins discordant for ALS ([@B183]); and particularly in Parkinson's Disease ([@B25]; [@B45]; [@B182]).

With all these evidences associating the KP in ALS, especially the unbalance between neuroprotective and neurotoxic metabolites, the KPMs represent a relevant set of biomarkers to characterize disease subtypes and to assess disease progression. As mentioned previously, such biomarkers are lacking especially for the response to treatments and for testing new drugs in clinical trials. One of the main reasons supporting the role of KPMs as a biomarker for ALS is its association with neuroinflammation. The KTR (indication of IDO activity, and thus KP activation) is a very sensitive and specific marker for inflammation. This KTR ratio is well suited as a surrogate progressive, or end-point marker for neuroinflammation. Apart from CSF, body fluids such as blood and urine are easiest to collect. Measurement of KPMs levels in blood present a rapid and reliable set of markers as there are validated quantification methods, and they are stable. However, there are still some limitations using the KPMs as a biomarker for diseases.

Firstly, a potential pitfall using the KPMs as a biomarker for neurological diseases and psychological disorders is that KP activation is not specific of one disease as it is present in all neuroinflammatory diseases. Thus, the KP cannot be used a diagnostic marker, but is relevant as a prognostic/progression marker, and to identify disease subtypes. Diagnostically, the KPMs still have a great potential as a confirmatory biomarker in conjunction with a shortlisted clinical diagnosis, or subtype. For example in MS, we were able to differentiate MS subtypes from patients diagnosed with MS ([@B106]). Similarly, when a patient is suspected to have ALS, or has been diagnosed with ALS by a neurologist, the KPMs can be used to differentiate between disease subtypes (e.g., bulbar or lower motor neuron symptoms) and be able to differentiate between patients predicted to be fast or slow progressors. The addition of other inflammatory markers such as cytokines, chemokines, C Protein Reactive, etc, in combination with KPMs would increase the sensitivity and specificity of the biomarker set.

Secondly, the biological functions of all the KPMs are not fully understood -- it is a very complex system that is intertwined other regulatory pathways such as BH4 ([@B31]), and ultimately regulate the immune system. Further, there is only a limited direct correlation between enzymatic activities and the metabolite formation and their ratios. This is not a key issue in using the KP as surrogate biomarkers, as the crux is that the KPM ratios (ratios of the bioactive metabolites) are what confer biological activity and biomarker association; rather than the function of measuring the enzyme activity. The levels of KPMs in the general population has been directly investigated by [@B189] (*n* = 7015) and [@B55] (*n* = 100), which showed that some KPMs are influenced by both age (KTR, KYN, HAA), and gender (TRP) ([@B35], [@B36]). Further, tryptophan has been shown to increase through to adolescence ([@B104]) and in adulthood ([@B113]). An earlier study by [@B118] investigated the KPMs in Malawian children and Vietnamese adults who were affected by Malaria, showing that increases in QA and PIC in both populations could predict a fatal outcome. On the contrary, differences in KA levels in Malawian children as compared to Vietnamese adults ([@B118]), although it is unclear if this difference was attribute to age, disease, or ethnicity. Further, the correlation of the KPMs in different biofluids need to be better established for correlation and pathway studies. Urine represents the ideal biofluid as it is non-invasive. However, it is not homeostatic, and apart from early studies when the KP was discovered in urine ([@B123], [@B124]; [@B172]; [@B117]; [@B114]), only few recent studies have analyzed the KPMs in urine ([@B48]; [@B138]; [@B38]). Recent research mostly use serum or plasma to assess the KPMs ([@B34]; [@B41]; [@B79]; [@B1]; [@B30]; [@B134]; [@B106]), and some when available, CSF ([@B40]; [@B73]; [@B168]). Further, the KP has been proposed as therapeutic intervention for neurodegenerative diseases such as ALS, and has been well reviewed ([@B49]).

As for other potential candidate biomarkers for ALS, the need for defined classifications of ALS subtypes or stages of disease progression ([@B53]) is critical. Standardized operation procedures for a defined analysis of progression rate, imaging, biopsy retrieval and storage, and biomarker analysis techniques need to be implemented to ensure consistency across centers to achieve an objective assessment. Biobanks storing clinical and biopsies of patient and control samples will be crucial to achieving the aim of a clinically applicable biomarker for ALS.

Conclusion {#S4}
==========

Overall, the KPMs have potential to be used as a sensitive and specific biomarker for patients diagnosed with ALS. Such markers would also have the ability to be used for surrogate clinical and prognostic biomarkers as we previously demonstrated for MS ([@B106]) and Alzheimer's disease ([@B22]; [@B83]). The strong correlation of the KP with neuroinflammation, depression, and immune regulation makes it a valid candidate as a surrogate biomarker for ALS, for disease progression (fast/slow progressors) and possibly disease subtyping. Combining the KPM levels together with (1) other markers of inflammation or neurodegeneration, (2) clinical information, and (3) imaging would strongly increase both sensitivity and specificity of the biomarker set.
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